{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:49Z","timestamp":1792834729612,"version":"4.5.0"},"reference-count":283,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02391-1","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:22:13Z","timestamp":1790774533000},"page":"1813-1839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies"],"prefix":"10.1007","volume":"86","author":[{"given":"Moein","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn N.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-9772","authenticated-orcid":false,"given":"Jeffrey A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"14","key":"2391_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler J. 2020;26(14):1816\u201321.","journal-title":"Mult Scler J"},{"issue":"1","key":"2391_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00415-017-8676-8","volume":"265","author":"D Conradsson","year":"2018","unstructured":"Conradsson D, Ytterberg C, von Koch L, Johansson S. Changes in disability in people with multiple sclerosis: a 10-year prospective study. J Neurol. 2018;265(1):119\u201326.","journal-title":"J Neurol"},{"issue":"12","key":"2391_CR3","doi-asserted-by":"publisher","first-page":"7269","DOI":"10.1007\/s10787-025-02012-5","volume":"33","author":"DD Ghafoor","year":"2025","unstructured":"Ghafoor DD, Ahmad DO, Najmuldeen HH, et al. Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers. Inflammopharmacology. 2025;33(12):7269\u2013314.","journal-title":"Inflammopharmacology."},{"issue":"8","key":"2391_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41582-022-00675-0","volume":"18","author":"J Oh","year":"2022","unstructured":"Oh J, Bar-Or A. Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nat Rev Neurol. 2022;18(8):466\u201375.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2391_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2023;13(1):47\u201370.","journal-title":"Neurodegener Dis Manag."},{"issue":"2","key":"2391_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2391_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302.","journal-title":"Ann Neurol"},{"issue":"6","key":"2391_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald criteria.\u201d Ann Neurol. 2005;58(6):840\u20136.","journal-title":"Ann Neurol"},{"issue":"1","key":"2391_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121\u20137.","journal-title":"Ann Neurol"},{"issue":"10","key":"2391_CR10","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850\u201365.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2391_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214688","volume":"106","author":"WJ Brownlee","year":"2026","unstructured":"Brownlee WJ, Maccarrone D, Nistri R, et al. Performance of the 2024 McDonald criteria in patients under evaluation for suspected multiple sclerosis. Neurology. 2026;106(6):e214688.","journal-title":"Neurology"},{"issue":"1","key":"2391_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000218183","volume":"107","author":"A Scharf","year":"2026","unstructured":"Scharf A, Cohen JA, Marrie RA, et al. Application of the 2024 McDonald criteria in individuals with nonspecific symptoms or incidental imaging findings in a multicenter study. Neurology. 2026;107(1):e218183.","journal-title":"Neurology"},{"issue":"4","key":"2391_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/13524585261421816","volume":"32","author":"I Abad-Inchaurrondo","year":"2026","unstructured":"Abad-Inchaurrondo I, Lu S, Lui E, et al. Performance of the 2024 McDonald diagnostic criteria for multiple sclerosis. Mult Scler J. 2026;32(4):375\u201384.","journal-title":"Mult Scler J"},{"issue":"2","key":"2391_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ana.25799","volume":"88","author":"C Lebrun-Frenay","year":"2020","unstructured":"Lebrun-Frenay C, Kantarci O, Siva A, et al. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann Neurol. 2020;88(2):407\u201317.","journal-title":"Ann Neurol"},{"issue":"10","key":"2391_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28271","volume":"4","author":"C Lebrun-Fr\u00e9nay","year":"2021","unstructured":"Lebrun-Fr\u00e9nay C, Rollot F, Mondot L, et al. Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw Open. 2021;4(10):e2128271.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2391_CR16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/acn3.51986","volume":"11","author":"C Landes\u2010Chateau","year":"2024","unstructured":"Landes\u2010Chateau C, Levraut M, Okuda DT, et al. The diagnostic value of the central vein sign in radiologically isolated syndrome. Ann Clin Transl Neurol. 2024;11(3):662\u201372.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"2391_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/brain\/awy021","volume":"141","author":"C Matute-Blanch","year":"2018","unstructured":"Matute-Blanch C, Villar LM, \u00c1lvarez-Cerme\u00f1o JC, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018;141(4):1085\u201393.","journal-title":"Brain"},{"issue":"10","key":"2391_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","volume":"80","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay C, Siva A, Sormani MP, et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial. JAMA Neurol. 2023;80(10):1080\u20138.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2391_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.26555","volume":"93","author":"DT Okuda","year":"2023","unstructured":"Okuda DT, Kantarci O, Lebrun-Fr\u00e9nay C, et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol. 2023;93(3):604\u201314.","journal-title":"Ann Neurol"},{"issue":"10","key":"2391_CR20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197\u2013204.","journal-title":"JAMA Neurol"},{"issue":"12","key":"2391_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrneurol.2016.166","volume":"12","author":"P Sati","year":"2016","unstructured":"Sati P, Oh J, Constable RT, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016;12(12):714\u201322.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"2391_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001120","volume":"9","author":"O Al-Louzi","year":"2022","unstructured":"Al-Louzi O, Letchuman V, Manukyan S, et al. Central vein sign profile of newly developing lesions in multiple sclerosis: a 3-year longitudinal study. Neurol Neuroimmunol Neuroinflamm. 2022;9(2):e1120.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"2391_CR23","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1093\/brain\/awae013","volume":"147","author":"F Bagnato","year":"2024","unstructured":"Bagnato F, Sati P, Hemond CC, et al. Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain. 2024;147(9):2913\u201333.","journal-title":"Brain."},{"key":"2391_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2025.106984","volume":"88","author":"K Toljan","year":"2025","unstructured":"Toljan K, Amin M, Ontaneda D. Central vein sign and paramagnetic rim lesion abbreviated counting methods for diagnosis of multiple sclerosis: a systematic review and meta-analysis. Clin Radiol. 2025;88:106984.","journal-title":"Clin Radiol"},{"issue":"6","key":"2391_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213912","volume":"105","author":"B Renner","year":"2025","unstructured":"Renner B, Verter ED, Absinta M, et al. Frequency and diagnostic implications of paramagnetic rim lesions in people presenting for diagnosis to a multiple sclerosis clinic. Neurology. 2025;105(6):e213912.","journal-title":"Neurology"},{"issue":"4-5","key":"2391_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1177\/13524585241229956","volume":"30","author":"JA Reeves","year":"2024","unstructured":"Reeves JA, Mohebbi M, Wicks T, et al. Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years. Mult Scler J. 2024;30(4\u20135):535\u201345.","journal-title":"Mult Scler J"},{"issue":"12","key":"2391_CR27","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","volume":"76","author":"M Absinta","year":"2019","unstructured":"Absinta M, Sati P, Masuzzo F, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 2019;76(12):1474\u201383.","journal-title":"JAMA Neurol"},{"key":"2391_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101359","volume":"54","author":"M Trojano","year":"2025","unstructured":"Trojano M, Paolicelli D. Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials. Lancet Reg Health Europe. 2025;54:101359.","journal-title":"Lancet Reg Health Europe."},{"issue":"7878","key":"2391_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41586-021-03892-7","volume":"597","author":"M Absinta","year":"2021","unstructured":"Absinta M, Maric D, Gharagozloo M, et al. A lymphocyte\u2013microglia\u2013astrocyte axis in chronic active multiple sclerosis. Nature. 2021;597(7878):709\u201314.","journal-title":"Nature"},{"issue":"9","key":"2391_CR30","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1007\/s00415-021-10490-0","volume":"268","author":"MA Andersen","year":"2021","unstructured":"Andersen MA, Buron MD, Magyari M. Late-onset MS is associated with an increased rate of reaching disability milestones. J Neurol. 2021;268(9):3352\u201360.","journal-title":"J Neurol"},{"issue":"1","key":"2391_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","volume":"22","author":"JS Graves","year":"2023","unstructured":"Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJM, Segal BM. Ageing and multiple sclerosis. Lancet Neurol. 2023;22(1):66\u201377.","journal-title":"Lancet Neurol"},{"key":"2391_CR32","doi-asserted-by":"publisher","first-page":"175628642413066","DOI":"10.1177\/17562864241306684","volume":"17","author":"A Dal-Bianco","year":"2024","unstructured":"Dal-Bianco A, Oh J, Sati P, Absinta M. Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance. Ther Adv Neurol Disord. 2024;17:17562864241306684.","journal-title":"Ther Adv Neurol Disord"},{"issue":"14","key":"2391_CR33","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1177\/13524585231204122","volume":"29","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Atkinson J, Burd CE, Graves J, Segal BM. Biological aging in multiple sclerosis. Mult Scler J. 2023;29(14):1701\u20138.","journal-title":"Mult Scler J"},{"issue":"2","key":"2391_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214527","volume":"106","author":"L Bos","year":"2026","unstructured":"Bos L, Wink AM, Cole JH, et al. Association of brain age with physical disability and cognitive impairment in people with multiple sclerosis of the same age. Neurology. 2026;106(2):e214527.","journal-title":"Neurology"},{"issue":"5","key":"2391_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ana.25592","volume":"86","author":"KM Krysko","year":"2019","unstructured":"Krysko KM, Henry RG, Cree BAC, et al. Telomere length is associated with disability progression in multiple sclerosis. Ann Neurol. 2019;86(5):671\u201382.","journal-title":"Ann Neurol"},{"issue":"10","key":"2391_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/13524585251367611","volume":"31","author":"A Laroni","year":"2025","unstructured":"Laroni A, Vigo T, Inglese M, Uccelli A. Immunosenescence in multiple sclerosis: new insights and clinical implications. Mult Scler J. 2025;31(10):1147\u201354.","journal-title":"Mult Scler J"},{"issue":"1","key":"2391_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9\u201316.","journal-title":"Blood"},{"key":"2391_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2021-151064","volume":"138","author":"H Bouzid","year":"2021","unstructured":"Bouzid H, Belk J, Jan M, et al. Clonal hematopoiesis is associated with reduced risk of Alzheimer\u2019s disease. Blood. 2021;138:5.","journal-title":"Blood"},{"issue":"6","key":"2391_CR39","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/joim.20080","volume":"297","author":"H Wu","year":"2025","unstructured":"Wu H, Wei J, Yu Y, Wang N, Tan X. Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases. J Intern Med. 2025;297(6):642\u201356.","journal-title":"J Intern Med"},{"issue":"13","key":"2391_CR40","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.cell.2022.05.020","volume":"185","author":"K Shi","year":"2022","unstructured":"Shi K, Li H, Chang T, et al. Bone marrow hematopoiesis drives multiple sclerosis progression. Cell. 2022;185(13):2234\u201347.","journal-title":"Cell"},{"key":"2391_CR41","doi-asserted-by":"publisher","first-page":"175628642093616","DOI":"10.1177\/1756286420936166","volume":"13","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Graves JS, Dobson R, et al. Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord. 2020;13:1756286420936166.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"2391_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1352458517737395","volume":"24","author":"T Chitnis","year":"2018","unstructured":"Chitnis T. The role of testosterone in MS risk and course. Mult Scler J. 2018;24(1):36\u201341.","journal-title":"Mult Scler J"},{"issue":"3","key":"2391_CR43","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1212\/WNL.0000000000004843","volume":"90","author":"JS Graves","year":"2018","unstructured":"Graves JS, Henry RG, Cree BAC, et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology. 2018;90(3):e254\u201360.","journal-title":"Neurology"},{"issue":"7","key":"2391_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/1352458515606211","volume":"22","author":"R Bove","year":"2016","unstructured":"Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler J. 2016;22(7):935\u201343.","journal-title":"Mult Scler J"},{"issue":"7","key":"2391_CR45","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.4103\/1673-5374.387974","volume":"19","author":"W Zhang","year":"2024","unstructured":"Zhang W, Wang Y, Zhu M, Liu K, Zhang HL. Gut flora in multiple sclerosis: implications for pathogenesis and treatment. Neural Regen Res. 2024;19(7):1480\u20138.","journal-title":"Neural Regen Res"},{"issue":"2","key":"2391_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.36469\/jheor.2022.38669","volume":"9","author":"D Dai","year":"2022","unstructured":"Dai D, Sharma A, Phillips AL, Lobo C. Patterns of comorbidity and multimorbidity among patients with multiple sclerosis in a large US commercially insured and medicare advantage population. J Health Econ Outcomes Res. 2022;9(2):125.","journal-title":"J Health Econ Outcomes Res."},{"issue":"13","key":"2391_CR47","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","volume":"74","author":"RA Marrie","year":"2010","unstructured":"Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74(13):1041\u20137.","journal-title":"Neurology"},{"issue":"22","key":"2391_CR48","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181a8260a","volume":"72","author":"T Goldschmidt","year":"2009","unstructured":"Goldschmidt T, Antel J, Konig FB, Bruck W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology. 2009;72(22):1914\u201321.","journal-title":"Neurology"},{"key":"2391_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420969016","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Gonzalez Caldito N, Shirani A, et al. Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Ther Adv Neurol Disord. 2020;13:1756286420969016.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"2391_CR50","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213967","volume":"105","author":"S Al-Araji","year":"2025","unstructured":"Al-Araji S, Moccia M, Jha A, et al. Effectiveness of disease-modifying therapies in patients with late-onset relapsing\u2013remitting multiple sclerosis. Neurology. 2025;105(4):e213967.","journal-title":"Neurology"},{"issue":"6","key":"2391_CR51","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/ene.12690","volume":"22","author":"A Signori","year":"2015","unstructured":"Signori A, Schiavetti I, Gallo F, Sormani MP. Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur J Neurol. 2015;22(6):960\u20136.","journal-title":"Eur J Neurol"},{"issue":"10127","key":"2391_CR52","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263\u201373.","journal-title":"Lancet"},{"issue":"3","key":"2391_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"issue":"9","key":"2391_CR54","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11910-024-01355-w","volume":"24","author":"RH Gross","year":"2024","unstructured":"Gross RH, Corboy J. De-escalation and discontinuation of disease-modifying therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2024;24(9):341\u201353.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"2391_CR55","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22(7):568\u201377.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2391_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamaneurol.2024.4164","volume":"82","author":"EME Coerver","year":"2025","unstructured":"Coerver EME, Fung WH, De Beukelaar J, et al. Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: the DOT-MS randomized clinical trial. JAMA Neurol. 2025;82(2):123\u201331.","journal-title":"JAMA Neurol"},{"key":"2391_CR57","doi-asserted-by":"publisher","first-page":"175628641983780","DOI":"10.1177\/1756286419837809","volume":"12","author":"L Prosperini","year":"2019","unstructured":"Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"2391_CR58","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790\u20134.","journal-title":"JAMA Neurol"},{"issue":"17","key":"2391_CR59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"issue":"12","key":"2391_CR60","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1177\/1352458519867314","volume":"26","author":"MP McGinley","year":"2020","unstructured":"McGinley MP, Cola PA, Fox RJ, Cohen JA, Corboy JJ, Miller D. Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Mult Scler J. 2020;26(12):1581\u20139.","journal-title":"Mult Scler J"},{"issue":"7","key":"2391_CR61","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0016","volume":"12","author":"IA Samjoo","year":"2023","unstructured":"Samjoo IA, Drudge C, Walsh S, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Eff Res. 2023;12(7):e230016.","journal-title":"J Comp Eff Res."},{"issue":"5","key":"2391_CR62","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17(5):405\u201315.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2391_CR63","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907\u201311.","journal-title":"Neurology"},{"issue":"3","key":"2391_CR64","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"3","key":"2391_CR65","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1001\/jamaneurol.2025.5068","volume":"83","author":"A Shirani","year":"2026","unstructured":"Shirani A, Stuve O. Beyond the single-disease paradigm\u2014why distinctions in multiple sclerosis still matter. JAMA Neurol. 2026;83(3):207\u20138.","journal-title":"JAMA Neurol."},{"issue":"1","key":"2391_CR66","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","volume":"18","author":"HYF Yong","year":"2022","unstructured":"Yong HYF, Yong VW. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol. 2022;18(1):40\u201355.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"2391_CR67","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200612","volume":"16","author":"A Signori","year":"2026","unstructured":"Signori A, Montobbio N, Bovis F, et al. Uncoupling relapse reduction and disability progression: evidence from tolebrutinib studies. Neurol Clin Pract. 2026;16(3):e200612.","journal-title":"Neurol Clin Pract."},{"issue":"1","key":"2391_CR68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78\u201388.","journal-title":"Lancet Neurol"},{"issue":"9","key":"2391_CR69","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147\u201361.","journal-title":"Brain"},{"issue":"10","key":"2391_CR70","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/13524585221078825","volume":"28","author":"J G\u00e4rtner","year":"2022","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler J. 2022;28(10):1562\u201375.","journal-title":"Mult Scler J"},{"issue":"9","key":"2391_CR71","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2391_CR72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1352458520918489","volume":"27","author":"V von Wyl","year":"2021","unstructured":"von Wyl V, Benkert P, Moser A, et al. Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta\/glatiramer acetate. Mult Scler J. 2021;27(3):439\u201348.","journal-title":"Mult Scler J"},{"issue":"4","key":"2391_CR73","doi-asserted-by":"publisher","first-page":"fcab229","DOI":"10.1093\/braincomms\/fcab229","volume":"3","author":"J Graf","year":"2021","unstructured":"Graf J, Leussink VI, Soncin G, et al. Relapse-independent multiple sclerosis progression under natalizumab. Brain Commun. 2021;3(4):fcab229.","journal-title":"Brain Commun."},{"issue":"6","key":"2391_CR74","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","volume":"82","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller J, Sharmin S, Lorscheider J, et al. Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis. JAMA Neurol. 2025;82(6):614\u201325.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2391_CR75","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209444","volume":"103","author":"O Ciccarelli","year":"2024","unstructured":"Ciccarelli O, Barkhof F, Calabrese M, et al. Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis. Neurology. 2024;103(1):e209444.","journal-title":"Neurology"},{"issue":"1","key":"2391_CR76","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000005","volume":"1","author":"S Ziccardi","year":"2025","unstructured":"Ziccardi S, Fuchs TA, Guandalini M, Marastoni D, Benedict RHB, Calabrese M. Cognitive progression independent of relapse and MRI activity in multiple sclerosis. Neurol Open Access. 2025;1(1):e0005.","journal-title":"Neurol Open Access"},{"issue":"9157","key":"2391_CR77","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0140-6736(98)03053-0","volume":"353","author":"L Kappos","year":"1999","unstructured":"Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999;353(9157):964\u20139.","journal-title":"Lancet"},{"issue":"7","key":"2391_CR78","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","volume":"12","author":"MP Sormani","year":"2013","unstructured":"Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12(7):669\u201376.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2391_CR79","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007\u201315.","journal-title":"Neurology"},{"issue":"4","key":"2391_CR80","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1212\/WNL.0000000000005853","volume":"91","author":"C Tsagkas","year":"2018","unstructured":"Tsagkas C, Magon S, Gaetano L, et al. Spinal cord volume loss: a marker of disease progression in multiple sclerosis. Neurology. 2018;91(4):e349\u201358.","journal-title":"Neurology"},{"issue":"10","key":"2391_CR81","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1136\/jnnp-2012-304094","volume":"84","author":"V Popescu","year":"2013","unstructured":"Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(10):1082\u201391.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2391_CR82","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ana.24018","volume":"75","author":"MP Sormani","year":"2014","unstructured":"Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014;75(1):43\u20139.","journal-title":"Ann Neurol"},{"key":"2391_CR83","volume":"32","author":"J Oh","year":"2025","unstructured":"Oh J, Fox RJ, Arnold DL, et al. Paramagnetic rim lesions as a prognostic and predictive biomarker in Tolebrutinib phase 3 trials for disability outcomes. Eur J Neurol. 2025;32:e70191.","journal-title":"Eur J Neurol."},{"issue":"3","key":"2391_CR84","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EAJ, Schaedelin S, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 2023;80(3):287\u201397.","journal-title":"JAMA Neurol"},{"issue":"12","key":"2391_CR85","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1093\/brain\/awaf331","volume":"148","author":"C Willard","year":"2025","unstructured":"Willard C, Puglisi L, Ravi D, et al. Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types. Brain. 2025;148(12):4578\u201391.","journal-title":"Brain"},{"issue":"1","key":"2391_CR86","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1038\/s41467-021-22265-2","volume":"12","author":"A Eshaghi","year":"2021","unstructured":"Eshaghi A, Young AL, Wijeratne PA, et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun. 2021;12(1):2078.","journal-title":"Nat Commun"},{"issue":"10","key":"2391_CR87","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1038\/s41591-025-03901-6","volume":"31","author":"H Ganjgahi","year":"2025","unstructured":"Ganjgahi H, H\u00e4ring DA, Aarden P, et al. AI-driven reclassification of multiple sclerosis progression. Nat Med. 2025;31(10):3414\u201324.","journal-title":"Nat Med."},{"key":"2391_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106690","volume":"104","author":"J Didierjean","year":"2025","unstructured":"Didierjean J, Kremer L, Lanotte L, et al. Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study. Mult Scler Relat Disord. 2025;104:106690.","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"2391_CR89","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-na\u00efve individuals with relapsing\u2013remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285\u201399.","journal-title":"CNS Drugs"},{"issue":"4","key":"2391_CR90","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2391_CR91","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394.","journal-title":"J Neurol"},{"issue":"7","key":"2391_CR92","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/13524585261442036","volume":"32","author":"MF Guarnaschelli","year":"2026","unstructured":"Guarnaschelli MF, Marrodan M, Sosa BE, et al. Early use of high-efficacy disease-modifying therapies reduces the risk of progression independent of relapse and MRI activity in patients with relapsing-remitting multiple sclerosis. Mult Scler J. 2026;32(7):737\u201346.","journal-title":"Mult Scler J."},{"key":"2391_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023;79:105009.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"2391_CR94","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00415-024-12882-4","volume":"272","author":"V Giannopapas","year":"2025","unstructured":"Giannopapas V, Smyrni V, Kitsos DK, et al. Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis. J Neurol. 2025;272(2):162.","journal-title":"J Neurol"},{"issue":"6","key":"2391_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae422","volume":"6","author":"L Pontieri","year":"2024","unstructured":"Pontieri L, Greene N, Wandall-Holm MF, et al. Patterns and predictors of multiple sclerosis phenotype transition. Brain Commun. 2024;6(6):fcae422.","journal-title":"Brain Commun"},{"key":"2391_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.","journal-title":"Front Neurol"},{"issue":"83","key":"2391_CR97","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2025.4856","volume":"2","author":"M Henderson","year":"2026","unstructured":"Henderson M, Horton DB, Bhise V, Bushnell G, Dave CV. Out-of-pocket and total health care costs among commercially insured adults and children with multiple sclerosis. JAMA Neurol. 2026;2(83):197\u20138.","journal-title":"JAMA Neurol"},{"issue":"11","key":"2391_CR98","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1177\/13524585251375350","volume":"31","author":"A Salazar-Camelo","year":"2025","unstructured":"Salazar-Camelo A, Vega L, Fadlallah Y, et al. Finite-course ocrelizumab in relapsing multiple sclerosis: results of two prospective open-label trials with matched controls. Mult Scler J. 2025;31(11):1338\u201347.","journal-title":"Mult Scler J"},{"issue":"8","key":"2391_CR99","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s12325-024-02902-0","volume":"41","author":"M Gudesblatt","year":"2024","unstructured":"Gudesblatt M, Bumstead B, Buhse M, et al. De-escalation of disease-modifying therapy for people with multiple sclerosis due to safety considerations: characterizing 1-year outcomes in 25 people who switched from ocrelizumab to diroximel fumarate. Adv Ther. 2024;41(8):3059\u201375.","journal-title":"Adv Ther"},{"issue":"3","key":"2391_CR100","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0071","volume":"14","author":"AB Ben-Zacharia","year":"2025","unstructured":"Ben-Zacharia AB, Feng JJ, Moss BP, et al. Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database. J Comp Eff Res. 2025;14(3):e240071.","journal-title":"J Comp Eff Res."},{"key":"2391_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106625","volume":"102","author":"MM Versteegh","year":"2025","unstructured":"Versteegh MM, Huygens SA. Exit strategies in patients with stable MS: cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine. Mult Scler Relat Disord. 2025;102:106625.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"2391_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00812","volume":"23","author":"FF Konen","year":"2025","unstructured":"Konen FF, Pfeuffer S, Jendretzky KF, et al. Switching from anti-CD20 therapies to cladribine and vice versa\u2014analysis of a German relapsing multiple sclerosis cohort. Neurotherapeutics. 2025;23(1):e00812.","journal-title":"Neurotherapeutics."},{"issue":"19","key":"2391_CR103","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, et al. Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med. 2025;392(19):1883\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"2391_CR104","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1474-4422(10)70007-7","volume":"9","author":"D Conway","year":"2010","unstructured":"Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299\u2013308.","journal-title":"Lancet Neurol"},{"issue":"5","key":"2391_CR105","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1759720X16665330","volume":"8","author":"K Inui","year":"2016","unstructured":"Inui K, Koike T. Combination therapy with biologic agents in rheumatic diseases: current and future prospects. Ther Adv Musculoskelet Dis. 2016;8(5):192\u2013202.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"9","key":"2391_CR106","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911\u201323.","journal-title":"N Engl J Med"},{"issue":"23","key":"2391_CR107","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1212\/WNL.0b013e318258f7d4","volume":"78","author":"MS Freedman","year":"2012","unstructured":"Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-\u03b2 in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012;78(23):1877\u201385.","journal-title":"Neurology"},{"issue":"1","key":"2391_CR108","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2004.04.023","volume":"223","author":"F Patti","year":"2004","unstructured":"Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci. 2004;223(1):69\u201371.","journal-title":"J Neurol Sci"},{"issue":"9","key":"2391_CR109","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","volume":"72","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806\u201312.","journal-title":"Neurology"},{"issue":"3","key":"2391_CR110","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ana.23863","volume":"73","author":"FD Lublin","year":"2013","unstructured":"Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327\u201340.","journal-title":"Ann Neurol"},{"issue":"4\u20135","key":"2391_CR111","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/13524585231157211","volume":"29","author":"S Satyanarayan","year":"2023","unstructured":"Satyanarayan S, Cutter G, Krieger S, Cofield S, Wolinsky JS, Lublin F. The impact of relapse definition and measures of durability on MS clinical trial outcomes. Mult Scler J. 2023;29(4\u20135):568\u201375.","journal-title":"Mult Scler J"},{"issue":"24_suppl_3","key":"2391_CR112","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1212\/WNL.0b013e31818f3d8b","volume":"71","author":"DS Goodin","year":"2008","unstructured":"Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008;71(24_suppl_3):S8\u201313.","journal-title":"Neurology"},{"issue":"10","key":"2391_CR113","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1177\/1352458511406309","volume":"17","author":"R Nicholas","year":"2011","unstructured":"Nicholas R, Straube S, Schmidli H, Schneider S, Friede T. Trends in annualized relapse rates in relapsing\u2013remitting multiple sclerosis and consequences for clinical trial design. Mult Scler J. 2011;17(10):1211\u20137.","journal-title":"Mult Scler J"},{"issue":"10","key":"2391_CR114","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40263-026-01328-2","volume":"40","author":"F Bovis","year":"2026","unstructured":"Bovis F, Signori A, Capanna M, Montobbio N, Sormani MP. Heterogeneity in teriflunomide treatment arms: a systematic review and meta-regression of randomised multiple sclerosis trials. CNS Drugs. 2026;40(10):1357\u201367.","journal-title":"CNS Drugs."},{"issue":"19","key":"2391_CR115","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","volume":"392","author":"J Oh","year":"2025","unstructured":"Oh J, Arnold DL, Cree BAC, et al. Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2025;392(19):1893\u2013904.","journal-title":"N Engl J Med"},{"issue":"11","key":"2391_CR116","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444.","journal-title":"Neurology"},{"issue":"2","key":"2391_CR117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrneurol.2017.171","volume":"14","author":"C Tur","year":"2018","unstructured":"Tur C, Moccia M, Barkhof F, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018;14(2):75\u201393.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"2391_CR118","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/archneur.1988.00520310052017","volume":"45","author":"MP Amato","year":"1988","unstructured":"Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. 1988;45(7):746\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"2391_CR119","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/archneur.1991.00530150067020","volume":"48","author":"DA Francis","year":"1991","unstructured":"Francis DA, Bain P, Swan AV, Hughes RAC. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991;48(3):299\u2013301.","journal-title":"Arch Neurol"},{"key":"2391_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103144","volume":"54","author":"M Cohen","year":"2021","unstructured":"Cohen M, Bresch S, Rocchi OT, et al. Should we still only rely on EDSS to evaluate disability in multiple sclerosis patients? A study of inter and intra rater reliability. Mult Scler Relat Disord. 2021;54:103144.","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"2391_CR121","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1212\/WNL.40.6.971","volume":"40","author":"JH Noseworthy","year":"1990","unstructured":"Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology. 1990;40(6):971.","journal-title":"Neurology"},{"issue":"4","key":"2391_CR122","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1212\/WNL.42.4.859","volume":"42","author":"DE Goodkin","year":"1992","unstructured":"Goodkin DE, Cookfair D, Wende K, et al. Inter-and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology. 1992;42(4):859.","journal-title":"Neurology"},{"issue":"5","key":"2391_CR123","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/135245859900500508","volume":"5","author":"MJ Hohol","year":"1999","unstructured":"Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999;5(5):349\u201354.","journal-title":"Mult Scler"},{"issue":"5","key":"2391_CR124","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/122.5.871","volume":"122","author":"GR Cutter","year":"1999","unstructured":"Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(5):871\u201382.","journal-title":"Brain"},{"issue":"4","key":"2391_CR125","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/135245859900500409","volume":"5","author":"JS Fischer","year":"1999","unstructured":"Fischer JS, Rudick RA, Cutter GR, Reingold SC, Force NMSSCOAT. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler J. 1999;5(4):244\u201350.","journal-title":"Mult Scler J"},{"issue":"1","key":"2391_CR126","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2377-14-58","volume":"14","author":"S Meyer-Moock","year":"2014","unstructured":"Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14(1):58.","journal-title":"BMC Neurol"},{"issue":"13","key":"2391_CR127","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1177\/1352458518808204","volume":"25","author":"L Strober","year":"2019","unstructured":"Strober L, DeLuca J, Benedict RHB, et al. Symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler J. 2019;25(13):1781\u201390.","journal-title":"Mult Scler J"},{"issue":"5","key":"2391_CR128","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","volume":"23","author":"LJ Balcer","year":"2017","unstructured":"Balcer LJ, Raynowska J, Nolan R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler J. 2017;23(5):734\u201347.","journal-title":"Mult Scler J"},{"issue":"10","key":"2391_CR129","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213558","volume":"104","author":"L Kappos","year":"2025","unstructured":"Kappos L, Yiu S, Dahlke F, et al. Composite confirmed disability worsening\/progression is a useful clinical endpoint for multiple sclerosis clinical trials. Neurology. 2025;104(10):e213558.","journal-title":"Neurology"},{"issue":"21","key":"2391_CR130","doi-asserted-by":"publisher","first-page":"e1921","DOI":"10.1212\/WNL.0000000000008519","volume":"93","author":"MD Goldman","year":"2019","unstructured":"Goldman MD, LaRocca NG, Rudick RA, et al. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology. 2019;93(21):e1921\u201331.","journal-title":"Neurology"},{"issue":"9","key":"2391_CR131","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/ene.13339","volume":"24","author":"V Khurana","year":"2017","unstructured":"Khurana V, Sharma H, Afroz N, Callan A, Medin J. Patient\u2010reported outcomes in multiple sclerosis: a systematic comparison of available measures. Eur J Neurol. 2017;24(9):1099\u2013107.","journal-title":"Eur J Neurol"},{"issue":"3","key":"2391_CR132","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","volume":"23","author":"J Chataway","year":"2024","unstructured":"Chataway J, Williams T, Li V, Marrie RA, Ontaneda D, Fox RJ. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol. 2024;23(3):277\u2013301.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2391_CR133","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1177\/1352458517721357","volume":"24","author":"LE Baldassari","year":"2018","unstructured":"Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT. Streamlined EDSS for use in multiple sclerosis clinical practice: development and cross-sectional comparison to EDSS. Mult Scler J. 2018;24(10):1347\u201355.","journal-title":"Mult Scler J"},{"key":"2391_CR134","doi-asserted-by":"publisher","first-page":"1514813","DOI":"10.3389\/fimmu.2025.1514813","volume":"16","author":"M Dini","year":"2025","unstructured":"Dini M, Comi G, Leocani L. Digital remote monitoring of people with multiple sclerosis. Front Immunol. 2025;16:1514813.","journal-title":"Front Immunol"},{"issue":"10","key":"2391_CR135","doi-asserted-by":"publisher","DOI":"10.2196\/22108","volume":"8","author":"A Pratap","year":"2020","unstructured":"Pratap A, Grant D, Vegesna A, et al. Evaluating the utility of smartphone-based sensor assessments in persons with multiple sclerosis in the real-world using an app (elevateMS): observational, prospective pilot digital health study. JMIR Mhealth Uhealth. 2020;8(10):e22108.","journal-title":"JMIR Mhealth Uhealth"},{"issue":"1","key":"2391_CR136","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41598-023-49299-4","volume":"14","author":"J Oh","year":"2024","unstructured":"Oh J, Capezzuto L, Kriara L, et al. Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study. Sci Rep. 2024;14(1):122.","journal-title":"Sci Rep"},{"issue":"9","key":"2391_CR137","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1177\/13524585241259650","volume":"30","author":"M Scaramozza","year":"2024","unstructured":"Scaramozza M, Chiesa PA, Zajac L, et al. KonectomTM cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: exploring the use of substitution time as a novel digital outcome measure. Mult Scler J. 2024;30(9):1193\u2013204.","journal-title":"Mult Scler J"},{"issue":"1","key":"2391_CR138","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/13524585231214362","volume":"30","author":"G Dalla Costa","year":"2024","unstructured":"Dalla Costa G, Nos C, Zabalza A, et al. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis. Mult Scler J. 2024;30(1):103\u201312.","journal-title":"Mult Scler J"},{"issue":"3","key":"2391_CR139","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0570","volume":"2","author":"VJ Block","year":"2019","unstructured":"Block VJ, Bove R, Zhao C, et al. Association of continuous assessment of step count by remote monitoring with disability progression among adults with multiple sclerosis. JAMA Netw Open. 2019;2(3):e190570.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2391_CR140","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","volume":"31","author":"CEP van Munster","year":"2017","unstructured":"van Munster CEP, Uitdehaag BMJ. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs. 2017;31(3):217\u201336.","journal-title":"CNS Drugs"},{"issue":"3","key":"2391_CR141","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/ana.21606","volume":"65","author":"MP Sormani","year":"2009","unstructured":"Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta\u2010analytic approach. Ann Neurol. 2009;65(3):268\u201375.","journal-title":"Ann Neurol"},{"issue":"8","key":"2391_CR142","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653\u201370.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2391_CR143","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","volume":"87","author":"MP Sormani","year":"2016","unstructured":"Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-\u03b2 in a multicenter dataset of patients with MS. Neurology. 2016;87(2):134\u201340.","journal-title":"Neurology"},{"issue":"7","key":"2391_CR144","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","volume":"13","author":"PA Muraro","year":"2017","unstructured":"Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13(7):391\u2013405.","journal-title":"Nat Rev Neurol"},{"key":"2391_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101476","volume":"59","author":"A Cagol","year":"2025","unstructured":"Cagol A, Schaedelin S, Pretzsch R, Kappos L, Sormani MP, Granziera C. The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis. Lancet Reg Health Europe. 2025;59:101476.","journal-title":"Lancet Reg Health Europe."},{"issue":"9","key":"2391_CR146","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-086414","volume":"14","author":"J Blackstone","year":"2024","unstructured":"Blackstone J, Williams T, Nicholas JM, et al. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. BMJ Open. 2024;14(9):e086414.","journal-title":"BMJ Open"},{"key":"2391_CR147","first-page":"1346","volume":"31","author":"R Fox","year":"2025","unstructured":"Fox R, Wolf C, Nastaj M, et al. Efficacy and safety of vidofludimus calcium, a novel nurr1 activator and dhodh inhibitor, in primary progressive multiple sclerosis (PPMS): subpopulation data from the phase 2 CALLIPER trial. Mult Scler J. 2025;31:1346\u20137.","journal-title":"Mult Scler J"},{"key":"2391_CR148","volume-title":"Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement","author":"D Ontaneda","year":"2021","unstructured":"Ontaneda D, Raza PC, Mahajan KR, et al. Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. Oxford University Press; 2021. (preprint posted online)."},{"issue":"6","key":"2391_CR149","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jon.12553","volume":"28","author":"C Casserly","year":"2018","unstructured":"Casserly C, Seyman EE, Alcaide-Leon P, et al. Spinal cord atrophy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimaging. 2018;28(6):556\u201386.","journal-title":"J Neuroimaging"},{"issue":"6","key":"2391_CR150","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","volume":"12","author":"SD Newsome","year":"2023","unstructured":"Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J. No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [narrative review]. Neurol Ther. 2023;12(6):1909\u201335.","journal-title":"Neurol Ther."},{"issue":"2","key":"2391_CR151","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1212\/WNL.0000000000200549","volume":"99","author":"D Rotstein","year":"2022","unstructured":"Rotstein D, Solomon JM, Sormani MP, et al. Association of no evidence of disease activity with no long-term disability progression in multiple sclerosis: a systematic review and meta-analysis. Neurology. 2022;99(2):e209\u201320.","journal-title":"Neurology"},{"issue":"4","key":"2391_CR152","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"BAC Cree","year":"2016","unstructured":"University of California SFMT, Cree BAC, Gourraud P, et al. Long\u2010term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499\u2013510.","journal-title":"Ann Neurol"},{"key":"2391_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101009","author":"M Di Filippo","year":"2024","unstructured":"Di Filippo M, Gaetani L, Centonze D, et al. Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Reg Health Eur. 2024. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101009.","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"2391_CR154","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200427","volume":"12","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or A, Nicholas J, Feng J, Sorrell F, Cascione M. Exploring the clinical utility of neurofilament light chain assays in multiple sclerosis management. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200427.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"2391_CR155","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000422","volume":"5","author":"KN Varhaug","year":"2017","unstructured":"Varhaug KN, Barro C, Bj\u00f8rnevik K, et al. Neurofilament light chain predicts disease activity in relapsing\u2013remitting MS. Neurol Neuroimmunol Neuroinflamm. 2017;5(1):e422.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"2391_CR156","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209357","volume":"102","author":"RJ Fox","year":"2024","unstructured":"Fox RJ, Cree BAC, de S\u00e8ze J, et al. Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis. Neurology. 2024;102(9):e209357.","journal-title":"Neurology"},{"issue":"11\u201312","key":"2391_CR157","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1177\/13524585231198751","volume":"29","author":"G Bose","year":"2023","unstructured":"Bose G, Healy BC, Barro C, et al. Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis. Mult Scler J. 2023;29(11\u201312):1418\u201327.","journal-title":"Mult Scler J"},{"issue":"2","key":"2391_CR158","doi-asserted-by":"publisher","first-page":"e2147588","DOI":"10.1001\/jamanetworkopen.2021.47588","volume":"5","author":"AR Gafson","year":"2022","unstructured":"Gafson AR, Jiang X, Shen C, et al. Serum neurofilament light and multiple sclerosis progression independent of acute inflammation. JAMA Netw Open. 2022;5(2):e2147588.","journal-title":"JAMA Netw Open"},{"issue":"19","key":"2391_CR159","doi-asserted-by":"publisher","first-page":"e1898","DOI":"10.1212\/WNL.0000000000012752","volume":"97","author":"C Bridel","year":"2021","unstructured":"Bridel C, Leurs CE, van Lierop ZYGJ, et al. Serum neurofilament light association with progression in natalizumab-treated patients with relapsing\u2013remitting multiple sclerosis. Neurology. 2021;97(19):e1898\u2013905.","journal-title":"Neurology"},{"issue":"4","key":"2391_CR160","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ana.25437","volume":"85","author":"G Dalla Costa","year":"2019","unstructured":"Dalla Costa G, Martinelli V, Moiola L, et al. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol. 2019;85(4):606\u201310.","journal-title":"Ann Neurol"},{"issue":"10","key":"2391_CR161","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/acn3.52187","volume":"11","author":"E Madill","year":"2024","unstructured":"Madill E, Healy BC, Molazadeh N, et al. Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Ann Clin Transl Neurol. 2024;11(10):2719\u201330.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"2391_CR162","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1515\/cclm-2025-1480","volume":"64","author":"EAJ Willemse","year":"2026","unstructured":"Willemse EAJ, Sandgren S, Benkert P, et al. Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls. Clin Chem Lab Med (CCLM). 2026;64(5):1046\u201353.","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"1","key":"2391_CR163","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200052","volume":"10","author":"C Barro","year":"2022","unstructured":"Barro C, Healy BC, Liu Y, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200052.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"7","key":"2391_CR164","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/brain\/awaf433","volume":"149","author":"AM Maceski","year":"2026","unstructured":"Maceski AM, Benkert P, Einsiedler M, et al. GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis. Brain. 2026;149(7):2295\u2013307.","journal-title":"Brain."},{"key":"2391_CR165","unstructured":"Biogen. Avonex [package insert]. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103628s5189lbl.pdf. Accessed 11 May 2026."},{"key":"2391_CR166","unstructured":"EMD Serono. Rebif [package insert]. 2003. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/ifnbser050203LB.pdf. Accessed 11 May 2026."},{"key":"2391_CR167","unstructured":"Genentech. Ocrevus [package insert]. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761053s029s030lbl.pdf. Accessed 28 Apr 2026."},{"key":"2391_CR168","unstructured":"Bayer. Betaseron [package insert]. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103471s5157lbl.pdf. Accessed 11 May 2026."},{"key":"2391_CR169","unstructured":"Biogen. Plegridy [package insert]. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125499lbl.pdf. Accessed 11 May 2026."},{"key":"2391_CR170","unstructured":"Teva. Copaxone [package insert]. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/020622s118s119lbl.pdf. Accessed 11 May 2026."},{"key":"2391_CR171","unstructured":"Biogen. Tecfidera [package insert]. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204063lbl.pdf. Accessed 11 May 2026."},{"key":"2391_CR172","unstructured":"Biogen. Vumerity [package insert]. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211855s000lbl.pdf. Accessed 11 May 2026."},{"key":"2391_CR173","unstructured":"Banner Life Sciences. Bafiertam [package insert]. 2025. https:\/\/www.bafiertam.com\/wp-content\/uploads\/2025\/09\/Bafiertam-FPI-0040-02092025.pdf. Accessed 11 May 2026."},{"key":"2391_CR174","unstructured":"Sanofi Genzyme. Aubagio [package insert]. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/202992s017lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR175","unstructured":"Sanofi Genzyme. Lemtrada [package insert]. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103948s5193lbl.pdf. Accessed 12 May 2026\/"},{"key":"2391_CR176","unstructured":"Novartis. Kesimpta [package insert]. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125326s070lbl.pdf. Accessed 12 May 12026."},{"key":"2391_CR177","unstructured":"TG Therapeutics. Briumvi [package insert]. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761238s000lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR178","unstructured":"Merck. Mavenclad [package insert]. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022561s000lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR179","unstructured":"Novartis. Gilenya [package insert]. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022527s002lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR180","unstructured":"Bristol Myers Squibb. Zeposia [package insert]. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209899s000lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR181","unstructured":"Vanda Pharmaceuticals. Ponvory [package insert]. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213498s000lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR182","unstructured":"Genentech. Rituxan [package insert]. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR183","unstructured":"Novartis. Mayzent [package insert]. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209884s019lbl.pdf. Accessed 12 May 2026."},{"key":"2391_CR184","unstructured":"Biogen. Tysabri [package insert]. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125104s0576lbl.pdf. Accessed 12 May 2026."},{"issue":"6","key":"2391_CR185","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7224\/1537-2073.2020-133","volume":"23","author":"RA Marrie","year":"2021","unstructured":"Marrie RA, Cutter GR, Fox RJ, Vollmer T, Tyry T, Salter A. NARCOMS and other registries in multiple sclerosis: issues and insights. Int J MS Care. 2021;23(6):276.","journal-title":"Int J MS Care."},{"issue":"2","key":"2391_CR186","first-page":"205521732412386","volume":"10","author":"M Salvetti","year":"2024","unstructured":"Salvetti M, Wray S, Nelles G, et al. Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: final results from the Plegridy Observational Program. Mult Scler J Exp Transl Clin. 2024;10(2):20552173241238630.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2391_CR187","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2147\/PPA.S307987","volume":"15","author":"B Kukowski","year":"2021","unstructured":"Kukowski B, Rehberg-Weber K, Taipale K, Kowalik A, Oschmann P. Subcutaneous interferon beta therapy in multiple sclerosis patients\u2014characterization of injection site reactions and flu-like symptoms in a daily practice setting\u2014results from the non-interventional study PERFECT. Patient Prefer Adherence. 2021;15:1091\u2013100.","journal-title":"Patient Prefer Adherence."},{"key":"2391_CR188","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211000461","volume":"14","author":"T Menge","year":"2021","unstructured":"Menge T, Rehberg-Weber K, Taipale K, Nastos I, Jau\u00df M. Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study. Ther Adv Neurol Disord. 2021;14:17562864211000460.","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"2391_CR189","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40263-021-00822-z","volume":"35","author":"SL Cohan","year":"2021","unstructured":"Cohan SL, Hendin BA, Reder AT, et al. Interferons and multiple sclerosis: Lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex). CNS Drugs. 2021;35(7):743\u201367.","journal-title":"CNS Drugs"},{"issue":"3","key":"2391_CR190","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208006","volume":"102","author":"HS Ng","year":"2024","unstructured":"Ng HS, Zhu F, Zhao Y, et al. Adverse events associated with disease-modifying drugs for multiple sclerosis: a multiregional population-based study. Neurology. 2024;102(3):e208006.","journal-title":"Neurology"},{"key":"2391_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107088","volume":"109","author":"I Schiavetti","year":"2026","unstructured":"Schiavetti I, Annovazzi P, Cordioli C, et al. Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the \u201cGA transition\u201d study. Mult Scler Relat Disord. 2026;109:107088.","journal-title":"Mult Scler Relat Disord."},{"key":"2391_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106750","volume":"104","author":"N Lyu","year":"2025","unstructured":"Lyu N, Li J, Hutton GJ, Liu X, Aparasu RR. Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025;104:106750.","journal-title":"Mult Scler Relat Disord."},{"issue":"10","key":"2391_CR193","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.3390\/jcm13102780","volume":"13","author":"I Maraffi","year":"2024","unstructured":"Maraffi I, Mallucci G, Disanto G, et al. Tolerability and acceptance of switching from brand to generic glatiramer acetate in multiple Sclerosis. J Clin Med. 2024;13(10):2780.","journal-title":"J Clin Med"},{"issue":"1","key":"2391_CR194","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12325-024-03047-w","volume":"42","author":"Y Mao-Draayer","year":"2025","unstructured":"Mao-Draayer Y, Bar-Or A, Balashov K, et al. Real-world safety and effectiveness of dimethyl fumarate in patients with MS: results from the ESTEEM phase 4 and PROCLAIM phase 3 studies with a focus on older patients. Adv Ther. 2025;42(1):395\u2013412.","journal-title":"Adv Ther"},{"issue":"1","key":"2391_CR195","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40120-024-00680-z","volume":"14","author":"KS Pandey","year":"2025","unstructured":"Pandey KS, Giles K, Balashov K, et al. Long-term safety and effectiveness of dimethyl fumarate in patients with multiple sclerosis treated in routine medical practice: final analysis of the ESTEEM study. Neurol Ther. 2025;14(1):243\u201360.","journal-title":"Neurol Ther."},{"issue":"12","key":"2391_CR196","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00415-025-13473-7","volume":"272","author":"T Monschein","year":"2025","unstructured":"Monschein T, Untersteiner H, Ponleitner M, et al. Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR). J Neurol. 2025;272(12):774.","journal-title":"J Neurol"},{"issue":"11","key":"2391_CR197","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40261-024-01397-5","volume":"44","author":"C Aguirre","year":"2024","unstructured":"Aguirre C, Alonso-Torres A, Ag\u00fcera E, et al. Real-world experience with diroximel fumarate in patients with multiple sclerosis: a prospective multicenter study. Clin Drug Investig. 2024;44(11):829\u201338.","journal-title":"Clin Drug Investig"},{"key":"2391_CR198","doi-asserted-by":"publisher","first-page":"175628642412527","DOI":"10.1177\/17562864241252722","volume":"17","author":"BA Kallmann","year":"2024","unstructured":"Kallmann BA, Zu Eulenburg G, Kullmann JS, M\u00e4urer M. TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time. Ther Adv Neurol Disord. 2024;17:17562864241252722.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"2391_CR199","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40120-024-00599-5","volume":"13","author":"R Li","year":"2024","unstructured":"Li R, Zhou J, Wu H, Wang Y, Chen J. Sustained effectiveness and safety over time of teriflunomide in Chinese patients with relapsing multiple sclerosis in the Greater Bay Area of China: insights from real-world data. Neurol Ther. 2024;13(4):1117\u201333.","journal-title":"Neurol Ther."},{"issue":"6","key":"2391_CR200","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s40120-023-00557-7","volume":"12","author":"JE Meca-Lallana","year":"2023","unstructured":"Meca-Lallana JE, Prieto Gonz\u00e1lez JM, Caminero Rodr\u00edguez AB, et al. Effectiveness and safety of teriflunomide in relapsing\u2013remitting multiple sclerosis and improvements in quality of life: results from the real-world TERICARE study. Neurol Ther. 2023;12(6):2177\u201393.","journal-title":"Neurol Ther."},{"key":"2391_CR201","doi-asserted-by":"publisher","first-page":"117957352110287","DOI":"10.1177\/11795735211028781","volume":"13","author":"J Oh","year":"2021","unstructured":"Oh J, Vukusic S, Tiel-Wilck K, et al. Efficacy and safety of teriflunomide in multiple sclerosis across age groups: analysis from pooled pivotal and real-world studies. J Cent Nerv Syst Dis. 2021;13:11795735211028780.","journal-title":"J Cent Nerv Syst Dis."},{"key":"2391_CR202","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/jnnp-2025-337367","volume":"97","author":"H Butzkueven","year":"2026","unstructured":"Butzkueven H, Kappos L, Wiendl H, et al. Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing\u2013remitting multiple sclerosis over 15 years. J Neurol Neurosurg Psychiatry. 2026;97:591\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2391_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101863","volume":"39","author":"J Foley","year":"2020","unstructured":"Foley J, Carrillo-Infante C, Smith J, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord. 2020;39:101863.","journal-title":"Mult Scler Relat Disord."},{"key":"2391_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104713","volume":"74","author":"MD Buron","year":"2023","unstructured":"Buron MD, Christensen JR, Pontieri L, et al. Natalizumab treatment of multiple sclerosis\u2014a Danish nationwide study with 13 years of follow-up. Mult Scler Relat Disord. 2023;74:104713.","journal-title":"Mult Scler Relat Disord."},{"issue":"8","key":"2391_CR205","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1007\/s00415-023-11686-2","volume":"270","author":"T Monschein","year":"2023","unstructured":"Monschein T, Dekany S, Zrzavy T, et al. Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR). J Neurol. 2023;270(8):3779\u201386.","journal-title":"J Neurol"},{"key":"2391_CR206","doi-asserted-by":"publisher","first-page":"175628642413065","DOI":"10.1177\/17562864241306575","volume":"18","author":"T Ziemssen","year":"2025","unstructured":"Ziemssen T, Bass AD, Van Wijmeersch B, et al. Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study. Ther Adv Neurol Disord. 2025;18:17562864241306576.","journal-title":"Ther Adv Neurol Disord"},{"key":"2391_CR207","doi-asserted-by":"publisher","first-page":"175628642311948","DOI":"10.1177\/17562864231194823","volume":"16","author":"AJ Coles","year":"2023","unstructured":"Coles AJ, Achiron A, Traboulsee A, et al. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023;16:17562864231194824.","journal-title":"Ther Adv Neurol Disord"},{"key":"2391_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101504","volume":"38","author":"M Di Ioia","year":"2020","unstructured":"Di Ioia M, Di Stefano V, Farina D, et al. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center. Mult Scler Relat Disord. 2020;38:101504.","journal-title":"Mult Scler Relat Disord."},{"key":"2391_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1112193","volume":"14","author":"S Eichau","year":"2023","unstructured":"Eichau S, L\u00f3pez Ruiz R, Ru\u00edz de Arcos M, et al. Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: the RealMS study. Front Neurol. 2023;14:1112193.","journal-title":"Front Neurol"},{"key":"2391_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104762","volume":"75","author":"AM L\u00f3pez-Real","year":"2023","unstructured":"L\u00f3pez-Real AM, Gonzalez I, Solar DM, et al. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort. Mult Scler Relat Disord. 2023;75:104762.","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"2391_CR211","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e158.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"10","key":"2391_CR212","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1080\/03007995.2023.2256220","volume":"39","author":"H Butzkueven","year":"2023","unstructured":"Butzkueven H, Hillert J, Soilu-H\u00e4nninen M, et al. The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis. Curr Med Res Opin. 2023;39(10):1367\u201374.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2391_CR213","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12883-025-04514-9","volume":"25","author":"H Alnajashi","year":"2025","unstructured":"Alnajashi H, Almohammed HAJ, Morad AS, et al. Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2025;25(1):510.","journal-title":"BMC Neurol"},{"issue":"2","key":"2391_CR214","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11096-025-02041-8","volume":"48","author":"Y Hu","year":"2026","unstructured":"Hu Y, He J, Tu Z, et al. Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system. Int J Clin Pharm. 2026;48(2):623\u201335.","journal-title":"Int J Clin Pharm"},{"key":"2391_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104491","volume":"70","author":"PS Sorensen","year":"2023","unstructured":"Sorensen PS, Pontieri L, Joensen H, et al. Real-world experience of cladribine treatment in relapsing\u2013remitting multiple sclerosis: a Danish nationwide study. Mult Scler Relat Disord. 2023;70:104491.","journal-title":"Mult Scler Relat Disord."},{"key":"2391_CR216","doi-asserted-by":"publisher","first-page":"1376494","DOI":"10.3389\/fphar.2024.1376494","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Yan Y, Liu S, Wang Z, Feng X. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024;15:1376494.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2391_CR217","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/17582024.2026.2622078","volume":"16","author":"J Cooperrider","year":"2026","unstructured":"Cooperrider J, Lambe J, Chu M, et al. Real-world experience of ozanimod in adults with multiple sclerosis. Neurodegener Dis Manag. 2026;16(4):401\u20139.","journal-title":"Neurodegener Dis Manag."},{"issue":"6","key":"2391_CR218","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s00415-021-10931-w","volume":"269","author":"T Ziemssen","year":"2022","unstructured":"Ziemssen T, Lang M, Schmidt S, et al. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany. J Neurol. 2022;269(6):3276\u201385.","journal-title":"J Neurol"},{"issue":"4","key":"2391_CR219","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230846","volume":"15","author":"F Barrero","year":"2020","unstructured":"Barrero F, Mallada-Frechin J, Mart\u00ednez-Gin\u00e9s ML, et al. Spanish real-world experience with fingolimod in relapsing\u2013remitting multiple sclerosis patients: MS NEXT study. PLoS ONE. 2020;15(4):e0230846.","journal-title":"PLoS ONE"},{"issue":"1","key":"2391_CR220","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12883-026-04727-6","volume":"26","author":"H Tan","year":"2026","unstructured":"Tan H, Zhou L, Gao Y, et al. Siponimod for relapsing\u2013remitting multiple sclerosis: a single-center, real-world cohort study in China. BMC Neurol. 2026;26(1):189.","journal-title":"BMC Neurol."},{"issue":"1","key":"2391_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02656-8","volume":"22","author":"V Tich\u00e1","year":"2022","unstructured":"Tich\u00e1 V, Po\u010d\u00edkov\u00e1 Z, Vytla\u010dil J, \u0160t\u011bp\u00e1nov\u00e1 R. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months. BMC Neurol. 2022;22(1):143.","journal-title":"BMC Neurol"},{"issue":"4","key":"2391_CR222","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210142","volume":"104","author":"JJ Cerqueira","year":"2025","unstructured":"Cerqueira JJ, Berthele A, Cree BAC, et al. Long-term treatment with ocrelizumab in patients with early-stage relapsing MS: nine-year data from the OPERA studies open-label extension. Neurology. 2025;104(4):e210142.","journal-title":"Neurology"},{"issue":"16","key":"2391_CR223","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97(16):e1546\u201359.","journal-title":"Neurology"},{"key":"2391_CR224","unstructured":"Carlson AK, Du M, Husak S, et al. Long-term safety risks among patients with multiple sclerosis treated with ocrelizumab: an observational study. Presented at ECTRIMS Congress; September 24\u201326, 2025; Barcelona, Spain. Abstract O077."},{"key":"2391_CR225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2574668","volume":"24","author":"C Scavone","year":"2025","unstructured":"Scavone C, Cagnotta C, Sportiello L, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies. Expert Opin Drug Saf. 2025;24:1\u201321.","journal-title":"Expert Opin Drug Saf."},{"issue":"3","key":"2391_CR226","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/13524585251412125","volume":"32","author":"KS Sangha","year":"2026","unstructured":"Sangha KS, Jakubecz C, Maynard M, et al. Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: the REPLACE-MS study. Mult Scler J. 2026;32(3):338\u201346.","journal-title":"Mult Scler J"},{"key":"2391_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578066","volume":"377","author":"V Mears","year":"2023","unstructured":"Mears V, Jakubecz C, Seeco C, Woodson S, Serra A, Abboud H. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD. J Neuroimmunol. 2023;377:578066.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"2391_CR228","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaneurol.2026.0007","volume":"83","author":"BAC Cree","year":"2026","unstructured":"Cree BAC, Fox E, Hartung HP, et al. Five years of ublituximab in multiple sclerosis: ULTIMATE I and II open-label extension study. JAMA Neurol. 2026;83(4):348\u201358.","journal-title":"JAMA Neurol"},{"issue":"9","key":"2391_CR229","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1007\/s10072-025-08329-x","volume":"46","author":"B Karaman","year":"2025","unstructured":"Karaman B, Din\u00e7er G, Tun\u00e7el R, Ekmekci O, Y\u00fcceyar N. Secondary hypogammaglobulinemia and lymphocytopenia in patients with inflammatory neurological diseases on anti-CD20 therapy: risk of infection and infection-related mortality. Neurol Sci. 2025;46(9):4569\u201374.","journal-title":"Neurol Sci"},{"key":"2391_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104763","volume":"75","author":"S Tolaymat","year":"2023","unstructured":"Tolaymat S, Sharma K, Kagzi Y, Sriwastava S. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: a case series and review. Mult Scler Relat Disord. 2023;75:104763.","journal-title":"Mult Scler Relat Disord."},{"key":"2391_CR231","unstructured":"Genentech. Risks with Use of OCREVUS\u00ae (ocrelizumab) and OCREVUS ZUNOVO\u00ae (ocrelizumab and hyaluronidase-ocsq): Liver Injury. 2025. https:\/\/www.gene.com\/download\/pdf\/Ocrevus-Zunovo_DHCP_Important_Drug_Warning_08-2025.pdf. Accessed 28 Apr 2026."},{"issue":"5","key":"2391_CR232","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2026.0548","volume":"83","author":"AE Zurawska","year":"2026","unstructured":"Zurawska AE, Cross AH, Rzeszutek K, Rogozi\u0144ska-Zawi\u015blak A, Selmaj KW. Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis. JAMA Neurol. 2026;83(5):505\u20137.","journal-title":"JAMA Neurol."},{"issue":"6","key":"2391_CR233","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1177\/13524585241295677","volume":"31","author":"A Gans","year":"2025","unstructured":"Gans A, Verrengia EP, Ricchiuti E, et al. Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: two case reports and comprehensive literature review. Mult Scler J. 2025;31(6):740\u20133.","journal-title":"Mult Scler J"},{"key":"2391_CR234","doi-asserted-by":"publisher","DOI":"10.1177\/13524585261444606","author":"DL Rotstein","year":"2026","unstructured":"Rotstein DL, Halani S, Vadas P, Marriott JJ. Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies. Mult Scler J. 2026. https:\/\/doi.org\/10.1177\/13524585261444606.","journal-title":"Mult Scler J."},{"issue":"2","key":"2391_CR235","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200534","volume":"13","author":"SA Banks","year":"2025","unstructured":"Banks SA, Poliakov I, Flanagan EP, Toledano M, Nathoo N. Enterovirus encephalitis in people with multiple sclerosis on ocrelizumab: insights from a multicenter case series. Neurol Neuroimmunol Neuroinflamm. 2025;13(2):e200534.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"2391_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00351","volume":"21","author":"K Toljan","year":"2024","unstructured":"Toljan K, Conway DS. Extended interval dosing of natalizumab: more evidence in support. Neurotherapeutics. 2024;21(3):e00351.","journal-title":"Neurotherapeutics"},{"issue":"8","key":"2391_CR237","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1007\/s10072-025-08098-7","volume":"46","author":"M Ghajarzadeh","year":"2025","unstructured":"Ghajarzadeh M, Rastkar M, Mowry EM, Nourbakhsh B. Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2025;46(8):3469\u201376.","journal-title":"Neurol Sci"},{"issue":"1","key":"2391_CR238","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","volume":"20","author":"C Rodriguez-Mogeda","year":"2023","unstructured":"Rodriguez-Mogeda C, van Lierop ZYGJ, van der Pol SMA, et al. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis. J Neuroinflamm. 2023;20(1):215.","journal-title":"J Neuroinflamm"},{"issue":"2","key":"2391_CR239","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214473","volume":"106","author":"A Langer-Gould","year":"2026","unstructured":"Langer-Gould A, Li BH, Smith JB, et al. Comparative effectiveness of rituximab dosed every 6 and 12 months in relapsing multiple sclerosis. Neurology. 2026;106(2):e214473.","journal-title":"Neurology"},{"issue":"3","key":"2391_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00554","volume":"22","author":"C Rigollet","year":"2025","unstructured":"Rigollet C, Freeman SA, Perriguey M, et al. Extended-interval dosing of rituximab\/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis. Neurotherapeutics. 2025;22(3):e00554.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2391_CR241","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/hex.12599","volume":"21","author":"IEH Kremer","year":"2018","unstructured":"Kremer IEH, Evers SMAA, Jongen PJ, Hiligsmann M. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best\u2013worst scaling. Health Expect. 2018;21(1):171\u201380.","journal-title":"Health Expect"},{"issue":"11","key":"2391_CR242","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164862","volume":"11","author":"IEH Kremer","year":"2016","unstructured":"Kremer IEH, Evers SMAA, Jongen PJ, van der Weijden T, van de Kolk I, Hiligsmann M. Identification and prioritization of important attributes of disease-modifying drugs in decision making among patients with multiple sclerosis: a nominal group technique and best-worst scaling. PLoS ONE. 2016;11(11):e0164862.","journal-title":"PLoS ONE"},{"issue":"6","key":"2391_CR243","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1756285614555335","volume":"7","author":"KS Utz","year":"2014","unstructured":"Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7(6):263\u201375.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"2391_CR244","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7224\/1537-2073.2013-053","volume":"17","author":"LS Wilson","year":"2015","unstructured":"Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015;17(2):74.","journal-title":"Int J MS Care."},{"key":"2391_CR245","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2016.12.038","volume":"375","author":"GK Reen","year":"2017","unstructured":"Reen GK, Silber E, Langdon DW. Multiple sclerosis patients\u2019 understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. J Neurol Sci. 2017;375:107\u201322.","journal-title":"J Neurol Sci"},{"issue":"3","key":"2391_CR246","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014433","volume":"7","author":"R Arroyo","year":"2017","unstructured":"Arroyo R, Sempere AP, Ruiz-Beato E, et al. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open. 2017;7(3):e014433.","journal-title":"BMJ Open"},{"issue":"12","key":"2391_CR247","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","volume":"267","author":"H Li","year":"2020","unstructured":"Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing\u2013remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2020;267(12):3489\u201398.","journal-title":"J Neurol"},{"issue":"3","key":"2391_CR248","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75(3):320\u20137.","journal-title":"JAMA Neurol"},{"issue":"11","key":"2391_CR249","volume":"2023","author":"I Tramacere","year":"2023","unstructured":"Tramacere I, Virgili G, Perduca V, et al. Adverse effects of immunotherapies for multiple sclerosis: a network meta\u2010analysis. Cochrane Database Syst Rev. 2023;2023(11):CD012186.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2391_CR250","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7224\/1537-2073.2017-043","volume":"20","author":"V Schlegel","year":"2018","unstructured":"Schlegel V, Leray E. From medical prescription to patient compliance: a qualitative insight into the neurologist\u2013patient relationship in multiple sclerosis. Int J MS Care. 2018;20(6):279\u201386.","journal-title":"Int J MS Care."},{"issue":"4","key":"2391_CR251","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14728214.2020.1822817","volume":"25","author":"E Carnero Contentti","year":"2020","unstructured":"Carnero Contentti E, Correale J. Bruton\u2019s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs. 2020;25(4):377\u201381.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"2391_CR252","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"5","key":"2391_CR253","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19(5):289\u2013304.","journal-title":"Nat Rev Neurol"},{"issue":"14","key":"2391_CR254","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.3390\/ijms22147641","volume":"22","author":"C Brullo","year":"2021","unstructured":"Brullo C, Villa C, Tasso B, Russo E, Spallarossa A. Btk inhibitors: a medicinal chemistry and drug delivery perspective. Int J Mol Sci. 2021;22(14):7641.","journal-title":"Int J Mol Sci"},{"key":"2391_CR255","unstructured":"European Medicines Agency. Cenrifki. 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cenrifki. Accessed 4 Sept 2026."},{"issue":"1","key":"2391_CR256","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40265-025-02264-z","volume":"86","author":"HA Blair","year":"2026","unstructured":"Blair HA. Tolebrutinib: first approval. Drugs. 2026;86(1):127\u201333.","journal-title":"Drugs"},{"key":"2391_CR257","unstructured":"Sanofi. Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis. 2025. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-12-15-06-05-00-3205094. Accessed 4 Sept 2026."},{"key":"2391_CR258","unstructured":"PracticalNeurology. Tolebrutinib Not Shown to Reduce Confirmed Disability Progression in Adults with Primary Progressive Multiple Sclerosis. 2026. https:\/\/practicalneurology.com\/news\/tolebrutinib-does-not-reduce-confirmed-disability-progression-in-adults-with-primary-progressive-multiple-sclerosis\/2485651\/. Accessed 4 Sept 2026."},{"key":"2391_CR259","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107038","volume":"107","author":"G Giovannoni","year":"2026","unstructured":"Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA. Tolebrutinib and the FDA. Mult Scler Relat Disord. 2026;107:107038.","journal-title":"Mult Scler Relat Disord."},{"key":"2391_CR260","unstructured":"Roche. Roche\u2019s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS). 2026. https:\/\/www.roche.com\/media\/releases\/med-cor-2026-02-07. Accessed 4 Sept 2026."},{"key":"2391_CR261","unstructured":"Roche. Roche\u2019s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS. 2026. https:\/\/www.roche.com\/media\/releases\/med-cor-2026-04-21c. Accessed 4 Sept 2026."},{"key":"2391_CR262","unstructured":"Novartis. Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in phase III RMS trials. 2026. https:\/\/www.novartis.com\/news\/media-releases\/novartis-remibrutinib-high-efficacy-oral-btk-inhibitor-significantly-reduces-relapse-rates-and-shows-favorable-safety-profile-phase-iii-rms-trials. Accessed 4 Sept 2026."},{"issue":"12","key":"2391_CR263","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1097\/MS9.0000000000002745","volume":"86","author":"T Fatima","year":"2024","unstructured":"Fatima T, Mirza A, Fatima F, et al. Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review. Ann Med Surg. 2024;86(12):7305\u201313.","journal-title":"Ann Med Surg."},{"issue":"4","key":"2391_CR264","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1468-1331.2001.00232.x","volume":"8","author":"J Jensen","year":"2001","unstructured":"Jensen J, Krakauer M, Sellebjerg F. Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis. Eur J Neurol. 2001;8(4):321\u20138.","journal-title":"Eur J Neurol"},{"key":"2391_CR265","doi-asserted-by":"publisher","first-page":"117957352110507","DOI":"10.1177\/11795735211050712","volume":"13","author":"Q Wu","year":"2021","unstructured":"Wu Q, Wang Q, Yang J, et al. Elevated sCD40L in secondary progressive multiple sclerosis in comparison to non-progressive benign and relapsing remitting multiple sclerosis. J Cent Nerv Syst Dis. 2021;13:11795735211050712.","journal-title":"J Cent Nerv Syst Dis."},{"issue":"7","key":"2391_CR266","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","volume":"390","author":"P Vermersch","year":"2024","unstructured":"Vermersch P, Granziera C, Mao-Draayer Y, et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N Engl J Med. 2024;390(7):589\u2013600.","journal-title":"N Engl J Med"},{"issue":"1","key":"2391_CR267","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf247","volume":"215","author":"DM Morelli","year":"2026","unstructured":"Morelli DM, Craig HC, Feng X, Youd M, Matijevic MI, Kerfoot SM. CD19 and Fc\u03b3RIIb co-engagement inhibits processes essential to T cell-dependent B-cell responses. J Immunol. 2026;215(1):vkaf247.","journal-title":"J Immunol"},{"issue":"9","key":"2391_CR268","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/cpdd.1557","volume":"14","author":"X Wang","year":"2025","unstructured":"Wang X, Gao M, Matijevic M, et al. Pharmacokinetics, receptor occupancy, and pharmacodynamics of obexelimab following intravenous administration in adult healthy volunteers and in patients with rheumatoid arthritis. Clin Pharmacol Drug Dev. 2025;14(9):656\u201368.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"8","key":"2391_CR269","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","volume":"5","author":"CA Perugino","year":"2023","unstructured":"Perugino CA, Wallace ZS, Zack DJ, et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol. 2023;5(8):e442\u201350.","journal-title":"Lancet Rheumatol."},{"key":"2391_CR270","unstructured":"Zenas BioPharma. Zenas BioPharma announces positive results from phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis. 2025. https:\/\/investors.zenasbio.com\/news-releases\/news-release-details\/zenas-biopharma-announces-positive-results-phase-2-moonstone. Accessed 3 Mar 2026."},{"key":"2391_CR271","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956907","volume":"13","author":"T Chitnis","year":"2022","unstructured":"Chitnis T, Kaskow BJ, Case J, et al. Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects. Front Immunol. 2022;13:956907.","journal-title":"Front Immunol"},{"key":"2391_CR272","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.709861","volume":"12","author":"TG Moreira","year":"2021","unstructured":"Moreira TG, Matos KTF, De Paula GS, et al. Nasal administration of anti-CD3 monoclonal antibody (Foralumab) reduces lung inflammation and blood inflammatory biomarkers in mild to moderate COVID-19 patients: a pilot study. Front Immunol. 2021;12:709861.","journal-title":"Front Immunol"},{"issue":"2","key":"2391_CR273","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200543","volume":"13","author":"T Chitnis","year":"2026","unstructured":"Chitnis T, Singhal T, Zurawski J, et al. Nasal foralumab for the treatment of progression independent of relapses in patients with nonactive secondary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2026;13(2):e200543.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"2391_CR274","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.4049\/jimmunol.181.9.6038","volume":"181","author":"HY Wu","year":"2008","unstructured":"Wu HY, Quintana FJ, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25\u2212 LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol. 2008;181(9):6038\u201350.","journal-title":"J Immunol"},{"issue":"8","key":"2391_CR275","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2217\/imt-2016-0049","volume":"8","author":"C Kuhn","year":"2016","unstructured":"Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016;8(8):889\u2013906.","journal-title":"Immunotherapy"},{"key":"2391_CR276","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102129","volume":"43","author":"A Muehler","year":"2020","unstructured":"Muehler A, Peelen E, Kohlhof H, Gr\u00f6ppel M, Vitt D. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;43:102129.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"2391_CR277","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200208","volume":"11","author":"RJ Fox","year":"2024","unstructured":"Fox RJ, Wiendl H, Wolf C, et al. Safety and dose-response of vidofludimus calcium in relapsing multiple sclerosis: extended results of a placebo-controlled phase 2 trial. Neurol Neuroimmunol Neuroinflamm. 2024;11(3):e200208.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"7","key":"2391_CR278","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/acn3.51574","volume":"9","author":"RJ Fox","year":"2022","unstructured":"Fox RJ, Wiendl H, Wolf C, et al. A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. Ann Clin Transl Neurol. 2022;9(7):977\u201387.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"2391_CR279","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/13543784.2026.2705509","volume":"35","author":"M Ondrus","year":"2026","unstructured":"Ondrus M, Fox RJ, Peelen E, et al. Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data. Expert Opin Investig Drugs. 2026;35(8):565\u201379.","journal-title":"Expert Opin Investig Drugs."},{"issue":"12","key":"2391_CR280","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1177\/1352458519845106","volume":"25","author":"BP Moss","year":"2019","unstructured":"Moss BP, Cohen JA. The emergence of follow-on disease-modifying therapies for multiple sclerosis. Mult Scler J. 2019;25(12):1560\u20135.","journal-title":"Mult Scler J"},{"issue":"3","key":"2391_CR281","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamaneurol.2022.5007","volume":"80","author":"B Hemmer","year":"2023","unstructured":"Hemmer B, Wiendl H, Roth K, et al. Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the Antelope phase 3 randomized clinical trial. JAMA Neurol. 2023;80(3):298\u2013307.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2391_CR282","first-page":"e191","volume":"30","author":"E Li","year":"2024","unstructured":"Li E. Budget impact analysis of biosimilar natalizumab in the US. Am J Manag Care. 2024;30(7):e191\u20137.","journal-title":"Am J Manag Care."},{"issue":"1","key":"2391_CR283","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75745-y","volume":"14","author":"MA Sahraian","year":"2024","unstructured":"Sahraian MA, Abolfazli R, Shaygannejad V, et al. Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial. Sci Rep. 2024;14(1):24921.","journal-title":"Sci Rep"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02391-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:02:07Z","timestamp":1792832527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02391-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":283,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2391"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02391-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Moein Amin reports research support from Novartis and Biogen. Kaitlyn N. Palmer reports receiving consulting fees from Genentech and fellowship support from EMD Serono Neuroimmunology Fellowship 2024-RMS-FEL -108454. Amjad Samara reports support by National MS Society Sylvia Lawry Physician Fellowship FP-2406-43370. Jeffrey A Cohen reports personal compensation for consulting for Astoria, AstraZeneca, Bristol-Myers Squibb, Convelo, Kite Pharma, Legend Biotech, Novartis, polTreg, PSI, and Shionogi, and Chairing a DSMB for Celltrion.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MA, KNP, AS, and JAC contributed to the concept, design, drafting, and revision of the manuscript. MA performed the search strategy and contributed to acquisition of resources. All authors participated in reviewing and approving the final manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}